5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs

Eur J Pharmacol. 1997 Apr 11;324(1):89-98. doi: 10.1016/s0014-2999(97)00052-6.

Abstract

The interference of the 5-lipoxygenase inhibitor, BW B70C ((E)-N-(3-[3-(4-fluorophenoxy)phenyl]-1(R,S)-methyl prop-2-enyl)-N-hydroxyurea), with Escherichia coli lipopolysaccharide (endotoxin)-induced lung leucocyte sequestration and microvascular albumin exchanges was evaluated in the anaesthetised guinea-pig using radioactive tracers, in parallel to the effects on cell counts in the broncho-alveolar lavage fluid, blood tumour necrosis factor (TNF-alpha) content, secretion of phospholipase A2 and synthesis of leukotriene C4 by alveolar macrophages. Intravenous injections of 0.1 or 1 mg/kg endotoxin induced lung leucocyte sequestration but only the higher dose induced an increase in albumin microvascular exchanges and the infiltration of leucocytes towards the airway lumen. Leukotriene B4, a potential mediator of the 5-lipoxygenase-dependent endotoxin effects, induced a rapid and transient lung leucocyte sequestration and leucopenia associated with a more progressive increase in microvascular exchanges. The 5-lipoxygenase inhibitor, BW B70C, injected i.p. (30 mg/kg) prevented leukotriene C4 synthesis by alveolar macrophages and reduced leucocyte migration to the airways lumen as well as albumin microvascular leakage but did not affect the endotoxin-induced increase in the blood level of TNF-alpha and of secreted phospholipase A2. However, BW B70C failed to modify vascular leucocyte margination induced by 1 mg/kg endotoxin, suggesting that, apart from a role of 5-lipoxygenase, alternative pathways operate in response to endotoxin in guinea-pig.

MeSH terms

  • Animals
  • Blood Proteins / metabolism
  • Bronchoalveolar Lavage Fluid / chemistry
  • Bronchoalveolar Lavage Fluid / cytology
  • Bronchopulmonary Sequestration / chemically induced
  • Bronchopulmonary Sequestration / drug therapy*
  • Cell Count
  • Cell Separation
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Escherichia coli / drug effects
  • Escherichia coli / metabolism
  • Guinea Pigs
  • Hydroxylamines / administration & dosage
  • Hydroxylamines / pharmacology*
  • Hydroxylamines / therapeutic use
  • Hydroxyurea* / analogs & derivatives*
  • Injections, Intravenous
  • Isotope Labeling
  • Leukocytes / cytology
  • Leukocytes / drug effects*
  • Leukopenia / chemically induced
  • Leukotriene B4 / toxicity
  • Leukotriene C4 / biosynthesis
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / toxicity*
  • Lipoxygenase Inhibitors / administration & dosage
  • Lipoxygenase Inhibitors / pharmacology*
  • Lipoxygenase Inhibitors / therapeutic use
  • Lung / cytology
  • Lung / drug effects*
  • Macrophage Activation / drug effects
  • Macrophages, Alveolar / cytology
  • Macrophages, Alveolar / metabolism
  • Methylurea Compounds / administration & dosage
  • Methylurea Compounds / pharmacology*
  • Methylurea Compounds / therapeutic use
  • Phospholipases A / metabolism
  • Phospholipases A2
  • Radioimmunoassay
  • Serum Albumin / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Blood Proteins
  • Hydroxylamines
  • Lipopolysaccharides
  • Lipoxygenase Inhibitors
  • Methylurea Compounds
  • Serum Albumin
  • Tumor Necrosis Factor-alpha
  • BW B70C
  • Leukotriene B4
  • Leukotriene C4
  • Phospholipases A
  • Phospholipases A2
  • Hydroxyurea